Mackenzie Financial Corp Has $235,000 Holdings in NeoGenomics, Inc. (NASDAQ:NEO)

Mackenzie Financial Corp decreased its position in NeoGenomics, Inc. (NASDAQ:NEO) by 14.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 14,498 shares of the medical research company’s stock after selling 2,542 shares during the quarter. Mackenzie Financial Corp’s holdings in NeoGenomics were worth $235,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. BluePath Capital Management LLC acquired a new position in NeoGenomics in the 3rd quarter valued at $30,000. WINTON GROUP Ltd acquired a new position in shares of NeoGenomics in the third quarter valued at about $133,000. Corton Capital Inc. bought a new position in NeoGenomics during the third quarter worth about $141,000. Aigen Investment Management LP acquired a new stake in NeoGenomics in the 3rd quarter worth about $163,000. Finally, Oppenheimer Asset Management Inc. boosted its holdings in NeoGenomics by 44.9% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 19,578 shares of the medical research company’s stock valued at $241,000 after purchasing an additional 6,062 shares during the period. Institutional investors own 98.50% of the company’s stock.

Insider Activity

In related news, General Counsel Alicia C. Olivo sold 2,587 shares of the business’s stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $14.96, for a total transaction of $38,701.52. Following the sale, the general counsel now owns 34,866 shares in the company, valued at approximately $521,595.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.30% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several research analysts have recently commented on the stock. William Blair reaffirmed an “outperform” rating on shares of NeoGenomics in a report on Wednesday, February 21st. The Goldman Sachs Group lifted their price objective on NeoGenomics from $17.00 to $19.00 and gave the company a “buy” rating in a report on Thursday, February 22nd. Needham & Company LLC increased their target price on NeoGenomics from $21.00 to $24.00 and gave the stock a “buy” rating in a report on Wednesday, February 21st. Finally, Piper Sandler upped their price objective on shares of NeoGenomics from $18.00 to $20.00 and gave the stock an “overweight” rating in a research report on Monday, February 26th. Three equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, NeoGenomics has an average rating of “Moderate Buy” and an average price target of $19.50.

NeoGenomics Stock Performance

NeoGenomics stock opened at $14.14 on Monday. The stock has a market cap of $1.81 billion, a PE ratio of -20.20 and a beta of 1.10. The company has a quick ratio of 5.95, a current ratio of 6.20 and a debt-to-equity ratio of 0.57. NeoGenomics, Inc. has a 12-month low of $11.03 and a 12-month high of $21.22. The business’s 50-day moving average price is $15.04 and its two-hundred day moving average price is $15.94.

NeoGenomics (NASDAQ:NEO) last released its quarterly earnings data on Tuesday, February 20th. The medical research company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.05. NeoGenomics had a negative net margin of 14.87% and a negative return on equity of 4.13%. The business had revenue of $155.55 million during the quarter, compared to analysts’ expectations of $152.90 million. As a group, analysts expect that NeoGenomics, Inc. will post -0.2 earnings per share for the current fiscal year.

NeoGenomics Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.